Bristol-Myers Squibb: Aches and Pains
Take two Excedrins, and call Bristol in a couple years.
The folks at Bristol-Myers Squibb probably wish the drug giant still made Extra Strength Excedrin. They could all use a double dose to cope with the latest unpleasant development to slam the company: The board of directors' September 12 ouster of Bristol-Myers' embattled CEO. Bristol is now arguably the most down-on-its-luck company in a sector that has plenty of industry-wide problems.
To understand drug-company woes, and to see the light at the end of the industry's tunnel, look no further than Bristol-Myers. Some of what makes Bristol the industry poster child are things it brought on itself, but some of its problems afflict nearly all of its rivals. Start with a 2002 accounting scandal, in which the company was found to have been "channel stuffing" -- forcing inventory into its distribution channels to inflate sales. The company paid $800 million and agreed to supervision by a federal monitor. If it kept its nose clean until April 2007, charges would be dropped.
The monitor thought Bristol-Myers crossed the line this summer. Apparently, its dealings with Canadian drug maker Apotex to keep a generic version of Bristol's blockbuster blood-thinning drug, Plavix, off the market weren't kosher. The monitor persuaded the board to sack CEO Peter Dolan and general counsel Richard Willard.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Some analysts hailed Dolan's ouster as overdue because Bristol shares plummeted during his five-year tenure. The stock (symbol BMY) has fallen from the $70s in 2001 to a September 12 close of $24.32, up 4% on the day. In fact, it's been a tough period for almost all of the big pharmaceutical companies. They have been suffering from a lack of new drugs and intense competition from generics that hit the markets as soon as big pharma's patents expire.
Bristol-Myers is arguably in the worst shape of any of the majors. Profits have been weak, to put it charitably, and the company may have to cut its dividend (now at an annual rate of $1.12 per share). Analysts on average expect Bristol to earn $1.02 per share this year and $1.17 next year, according to Thomson First Call. That's down from a peak of $2.41 per share in 2001. Only three of 23 analysts polled by Thomson First Call rate Bristol-Myers a "buy" or "strong buy."
So, where's the light at the end of the tunnel? A long way off, but it's there. Homestead Value fund owns Bristol-Myers and other big pharma companies, but then, the fund holds stocks for ten years, on average. Co-manager Stuart Teach says you have to look past the noise in the market to find the true value of these companies.
In the late 1990s, Teach says, most analysts suggested that drug stocks could rise steadily forever. And why not? They had the fundamentals on their side: An aging population and the seemingly limitless ability of health-insurance providers to pay for all the drugs the baby boomers would need. Today, the population is still aging and somebody will still have to pay for all the drugs aging boomers will consume. "We fully believe that the underlying fundamentals at Bristol-Myers are intact," says Teach. "The latest news is not going to break the underlying fundamentals." And the strongest of those fundamentals is a track record of developing drugs that people need. The timing of Bristol's recovery is uncertain, but it almost certainly will recover some day.
-
Use An iPhone? You May Be Hearing From A Class-Action Lawsuit Group
A handful of suits against the iPhone maker seek to crack down on everything from app store purchases to messaging.
By Keerthi Vedantam Published
-
Capital One/Discover: What's In Their Wallet For You?
Push back on Capital One's planned merger with Discover is growing with one group of consumer advocates calling for a public hearing.
By Keerthi Vedantam Published
-
Stock Market Today: Dow Outperforms as Merck Hits New High
The S&P 500 and Dow Jones Industrial Average snapped three-day losing streaks as drugmaker Merck rallied.
By Karee Venema Published
-
Stock Market Today: S&P 500, Dow Extend Losing Streaks
Reddit stock continued to charge higher and has now nearly doubled in price since last week's IPO.
By Karee Venema Published
-
Stock Market Today: Bitcoin, Boeing Shine as Stocks Slip
Digital World Acquisition sizzled, too, ahead of its merger with Trump Media & Technology Group.
By Karee Venema Published
-
Stock Market Today: Dow Retreats After Nike Earnings
The Nasdaq Composite managed to notch a new record close Friday, building on the week's impressive gains.
By Karee Venema Published
-
Stock Market Today: Stocks Hit New Highs as Rate-Cut Momentum Continues
Reddit sizzled in its market debut, while Apple slumped after the tech giant was slapped with an antitrust lawsuit.
By Karee Venema Published
-
Stock Market Today: Stocks Climb After Fed Forecasts Three Rate Cuts This Year
The main indexes notched new record closes Wednesday after the Federal Reserve kept its outlook for rate cuts unchanged.
By Karee Venema Published
-
Stock Market Today: Stocks Close Higher After Nvidia's Reversal
The main indexes erased early losses Tuesday as mega-cap tech stock Nvidia swung higher.
By Karee Venema Published
-
Stock Market Today: Nasdaq Soars on Strength in Magnificent 7 Stocks
The main indexes started the week strong after several mega-cap stocks rallied.
By Karee Venema Published